前往化源商城

Clinica Chimica Acta 2012-12-24

LC–MS/MS analysis of plasma lyso-Gb3 in Fabry disease

Michel Boutin, René Gagnon, Pamela Lavoie, Christiane Auray-Blais

文献索引:Clin. Chim. Acta 414 , 273-80, (2012)

全文:HTML全文

摘要

Background Fabry disease is a complex, multisystemic and clinically heterogeneous disease, with elevated excretion of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) accumulating in biological fluids caused by deficiency of the enzyme, lysosomal α-galactosidase A. Our aims were to propose a tandem mass spectrometry fragmentation mechanism for lyso-Gb3, to develop and validate a simple, and robust methodology for the measurement of plasma lyso-Gb3 using LC–MS/MS in large Fabry cohorts and in controls. Response to treatment was also evaluated.

相关化合物

结构式 名称/CAS号 全部文献
α-D-Gal-(1→4)-β-D-Gal-(1→4)-β-D-Glc-1→O-sphingosine 结构式 α-D-Gal-(1→4)-β-D-Gal-(1→4)-β-D-Glc-1→O-sphingosine
CAS:126550-86-5